CDC: Fentanyl Driving Rise in Opioid-Linked Deaths in U.S.

Share this content:
CDC: Fentanyl Driving Rise in Opioid-Linked Deaths in U.S.
CDC: Fentanyl Driving Rise in Opioid-Linked Deaths in U.S.

FRIDAY, Sept. 1, 2017 (HealthDay News) -- Fentanyl is a key player in America's continuing epidemic of opioid-related overdose deaths, according to two reports published in the Sept. 1 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

Opioid overdose deaths began increasing early this decade as people addicted to prescription opioids started switching to heroin, which became cheaper and increased in supply, CDC researchers said. But the emergence of fentanyl and its cousins drove an even greater increase in overdose deaths.

"Approximately half of the increase in deaths involving heroin after 2013 is attributable to increases in deaths involving use of both heroin and fentanyl," researchers with the CDC's National Center for Injury Prevention and Control write in one of the reports. But deaths from fentanyl-type drugs with no heroin involvement also increased substantially in recent years. About 90 percent of overdose deaths in Ohio early this year involved fentanyl or its chemical cousins, state public health officials said in the second report. Only 6 percent of overdoses involved heroin.

After 2013, deaths caused by the combined use of heroin and synthetic opioids accounted for 77 percent of the total increase in heroin-related deaths in the U.S. Northeast and Midwest, the two regions with the sharpest increases in fentanyl use, CDC researchers said.

Abstract/Full Text 1
Abstract/Full Text 2

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »